Complicated Progress of Granulomatosis with Polyangiitis - A Case Presentation And Review of literature
,
Abstract
Granulomatosis with polyangiitis, previously known as Wegener’s, is a necrotizing vascular disease that affects small blood vessels and may cause damage to the respiratory tract and kidneys. In this article, we report on a 50-year-old male with a complicated disease process who experienced rare bladder and renal complications and several adverse drug reactions. Despite using drug alternatives, the side effects remained mostly the same. Therefore, by studying different cases and articles, we establish the relation between these findings and the specifications of granulomatosis with polyangiitis. This case underscores the complexity of managing this condition and the need for personalized treatment strategies.
[1] Eisenberg PA, Collier V, Mangano A, Shergill K, Yos E. Sub- glottic Stenosis as a Presentation of Antineutrophil Cyto- plasmic Antibody-Associated Glomerulonephritis. Cureus. 2023;15(10):e46899.
[2] Moin KA, Yeakle MM, Parrill AM, Garofalo VA, Tsiyer AR, Bishev D, et al. Ocular and orbital manifestations of granulomatosis with polyangiitis: a systematic review of published cases. Rom J Ophthalmol. 2023;67(3):214-21. https://doi.org/10.22336/ rjo.2023.38
[3] Chalkia A, Jayne D. ANCA-associated vasculitis - Treat- ment Standard. Nephrol Dial Transplant. 2023. https://doi. org/10.1093/ndt/gfad237
[4] Fauci AS, Wolff SM. Wegener’s granulomatosis: stud- ies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973;52(6):535-61. https://doi. org/10.1097/00005792-197311000-00002
[5] Narváez J, Pirola JP, J LL, Juarez P, Nolla JM, Valenzuela A. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. Autoim- mun Rev. 2019;18(3):262-9. https://doi.org/10.1016/j.au- trev.2018.10.006
[6] Nasr R, Balasubramanian P, Desiderio L, Abdelattif M. A Rare Case of Nephrotic-Range Proteinuria in Antineutrophil Cy- toplasmic Antibodies (ANCA)-Associated Vasculitis. Cureus. 2022;14(5):e24889. https://doi.org/10.7759/cureus.24889
[7] Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener’s granulo- matosis treated with plasma exchange. Blood Purification. 2002;20(2):167-73. https://doi.org/10.1159/000047004
[8] Matousovic K, Martinek V, Spatenka J, Stejskal J, Chadimo- va M. Malignant Wegener’s Granulomatosis with Fibros- ing Mediastinitis and Vena Cava Superior Syndrome. Renal Failure. 2012;34(2):244-6. https://doi.org/10.3109/088602 2X.2011.647208
[9] Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophy- lactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophos- phamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008;14(5):267-72. https://doi. org/10.1097/RHU.0b013e31817a7e30
[10] Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S, et al. Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2023. https://doi.org/10.1136/ard-2023-224472
[11] Ayza MA, Zewdie KA, Yigzaw EF, Ayele SG, Tesfaye BA, Tafere GG, et al. Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity. Internation- al Journal of Nephrology. 2022;2022:5096825.https://doi. org/10.1155/2022/5096825
[12] Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener’s granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol. 1991;35(4):139-47.
[13] Tiewsoh I, Dey B, Lyngdoh M, Lynrah K, Synrem E, Mitra A. Granulomatous interstitial nephritis in granulomatosis with polyangiitis mimicking leprosy: A case report. J Family Med Prim Care. 2020;9(11):5783-6.https://doi.org/10.4103/jfmpc. jfmpc_1070_20
[14] Carazo ER, Benitez AM, Milena GL, Espigares JR, León L, Marquez B. Multiple Renal Masses as Initial Manifestation of Wegener’s Granulomatosis. American Journal of Roent- genology. 2001;176(1):116-8. https://doi.org/10.2214/ ajr.176.1.1760116
[15] Higashihara M, Kawamura T, Miyazaki Y, Yokoo T, Joh K. Granu- lomatosis with polyangiitis presenting as a solitary renal mass: a case report. BMC Nephrology. 2023;24(1):223. https://doi. org/10.1186/s12882-023-03276-1
[16] Medscape. rituximab (Rx) www.medscape.com2019 [Avail- able from: https://reference.medscape.com/drug/ritux- an-truxima-rituximab-342243.
[17] Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159-83. https://doi.org/10.1007/s00415- 020-10362-z
[18] Dubos M, Ly K, Martel C, Fauchais AL. Is rituximab an effective treatment of refractory calcinosis? BMJ Case Rep. 2016;2016. https://doi.org/10.1136/bcr-2015-213179
[2] Moin KA, Yeakle MM, Parrill AM, Garofalo VA, Tsiyer AR, Bishev D, et al. Ocular and orbital manifestations of granulomatosis with polyangiitis: a systematic review of published cases. Rom J Ophthalmol. 2023;67(3):214-21. https://doi.org/10.22336/ rjo.2023.38
[3] Chalkia A, Jayne D. ANCA-associated vasculitis - Treat- ment Standard. Nephrol Dial Transplant. 2023. https://doi. org/10.1093/ndt/gfad237
[4] Fauci AS, Wolff SM. Wegener’s granulomatosis: stud- ies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973;52(6):535-61. https://doi. org/10.1097/00005792-197311000-00002
[5] Narváez J, Pirola JP, J LL, Juarez P, Nolla JM, Valenzuela A. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. Autoim- mun Rev. 2019;18(3):262-9. https://doi.org/10.1016/j.au- trev.2018.10.006
[6] Nasr R, Balasubramanian P, Desiderio L, Abdelattif M. A Rare Case of Nephrotic-Range Proteinuria in Antineutrophil Cy- toplasmic Antibodies (ANCA)-Associated Vasculitis. Cureus. 2022;14(5):e24889. https://doi.org/10.7759/cureus.24889
[7] Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener’s granulo- matosis treated with plasma exchange. Blood Purification. 2002;20(2):167-73. https://doi.org/10.1159/000047004
[8] Matousovic K, Martinek V, Spatenka J, Stejskal J, Chadimo- va M. Malignant Wegener’s Granulomatosis with Fibros- ing Mediastinitis and Vena Cava Superior Syndrome. Renal Failure. 2012;34(2):244-6. https://doi.org/10.3109/088602 2X.2011.647208
[9] Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophy- lactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophos- phamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008;14(5):267-72. https://doi. org/10.1097/RHU.0b013e31817a7e30
[10] Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S, et al. Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2023. https://doi.org/10.1136/ard-2023-224472
[11] Ayza MA, Zewdie KA, Yigzaw EF, Ayele SG, Tesfaye BA, Tafere GG, et al. Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity. Internation- al Journal of Nephrology. 2022;2022:5096825.https://doi. org/10.1155/2022/5096825
[12] Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener’s granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol. 1991;35(4):139-47.
[13] Tiewsoh I, Dey B, Lyngdoh M, Lynrah K, Synrem E, Mitra A. Granulomatous interstitial nephritis in granulomatosis with polyangiitis mimicking leprosy: A case report. J Family Med Prim Care. 2020;9(11):5783-6.https://doi.org/10.4103/jfmpc. jfmpc_1070_20
[14] Carazo ER, Benitez AM, Milena GL, Espigares JR, León L, Marquez B. Multiple Renal Masses as Initial Manifestation of Wegener’s Granulomatosis. American Journal of Roent- genology. 2001;176(1):116-8. https://doi.org/10.2214/ ajr.176.1.1760116
[15] Higashihara M, Kawamura T, Miyazaki Y, Yokoo T, Joh K. Granu- lomatosis with polyangiitis presenting as a solitary renal mass: a case report. BMC Nephrology. 2023;24(1):223. https://doi. org/10.1186/s12882-023-03276-1
[16] Medscape. rituximab (Rx) www.medscape.com2019 [Avail- able from: https://reference.medscape.com/drug/ritux- an-truxima-rituximab-342243.
[17] Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159-83. https://doi.org/10.1007/s00415- 020-10362-z
[18] Dubos M, Ly K, Martel C, Fauchais AL. Is rituximab an effective treatment of refractory calcinosis? BMJ Case Rep. 2016;2016. https://doi.org/10.1136/bcr-2015-213179
| Files | ||
| Issue | Vol 8 No 6 (2023): November-December | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/crcp.v8i6.16237 | |
| Keywords | ||
| Granulomatosis with polyangiiti ANCA associated Vasculiti Polyangiiti Rituxima Cyclophosphamide | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Tabatabaei MS, Mortazi M. Complicated Progress of Granulomatosis with Polyangiitis - A Case Presentation And Review of literature. CRCP. 2024;8(6):270-274.
